Interestingly, increased FOXO3 activation in cisplatin-resistant colon cancer cells with the small molecule Akt inhibitor, tricirbine/API-2, can override cisplatin resistance by blocking Akt-mediated FOXO3 phosphorylation [182]. This evidence concerns the gene AKT1 and colonic neoplasm.